Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting.

Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U, Antoch G, Keyvani K, Nittka M, Kannengiesser S, Gulani V, Griswold M, Herrmann K, Forsting M, Nensa F, Umutlu L.

Eur J Nucl Med Mol Imaging. 2019 Dec 6. doi: 10.1007/s00259-019-04602-2. [Epub ahead of print]

PMID:
31811342
2.

A rare case of a completely thrombosed bilobed giant intracranial aneurysm of the anterior cerebral artery with spontaneous parent vessel thrombosis: case report.

Chihi M, Jabbarli R, Gembruch O, Teuber-Hanselmann S, Darkwah Oppong M, Pierscianek D, Radbruch A, Glas M, Stettner M, Sure U.

BMC Neurol. 2019 Nov 23;19(1):297. doi: 10.1186/s12883-019-1529-6.

3.

To resect or not to resect? Risks and benefits of surgery in older patients with glioblastoma.

Ahmadipour Y, Rauschenbach L, Gembruch O, Darkwah Oppong M, Michel A, Pierscianek D, Stuschke M, Glas M, Sure U, Jabbarli R.

J Geriatr Oncol. 2019 Oct 28. pii: S1879-4068(19)30247-4. doi: 10.1016/j.jgo.2019.10.013. [Epub ahead of print]

PMID:
31672557
4.

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.

Stoppek AK, Kebir S, Junker A, Keyvani K, Zülow S, Lazaridis L, Schmidt T, Pierscianek D, Stuschke M, Sure U, Kleinschnitz C, Scheffler B, Zimmer L, Glas M.

BMC Cancer. 2019 Oct 23;19(1):995. doi: 10.1186/s12885-019-6183-2.

5.

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.

Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y.

Cancer Immunol Res. 2019 Dec;7(12):1910-1927. doi: 10.1158/2326-6066.CIR-18-0865. Epub 2019 Oct 9.

PMID:
31597643
6.

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.

Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N.

Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.

PMID:
31488360
7.

Interrogating the Essential Bacterial Cell Division Protein FtsQ with Fragments Using Target Immobilized NMR Screening (TINS).

Glas M, Ab E, Hollander J, Siegal G, Luirink J, de Esch I.

Int J Mol Sci. 2019 Jul 27;20(15). pii: E3684. doi: 10.3390/ijms20153684.

8.

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.

J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19.

PMID:
31325144
9.

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Zaremba A, Chorti E, Jockenhöfer F, Bolz S, Sirin S, Glas M, Becker JC, Ugurel S, Roesch A, Schadendorf D, Livingstone E, Hagenacker T, Zimmer L.

J Immunother Cancer. 2019 May 29;7(1):141. doi: 10.1186/s40425-019-0626-9.

10.

Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.

Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Mönninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Herrmann K, Glas M.

Clin Nucl Med. 2019 Jun;44(6):e375-e381. doi: 10.1097/RLU.0000000000002577.

PMID:
30985412
11.

Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma.

Ahmadipour Y, Kaur M, Pierscianek D, Gembruch O, Oppong MD, Mueller O, Jabbarli R, Glas M, Sure U, El Hindy N.

J Neurol Surg A Cent Eur Neurosurg. 2019 Jul;80(4):262-268. doi: 10.1055/s-0039-1685170. Epub 2019 Apr 9.

PMID:
30965373
12.

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.

Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B, Glas M.

J Transl Med. 2019 Mar 20;17(1):96. doi: 10.1186/s12967-019-1846-y.

13.

Regorafenib in patients with recurrent high-grade astrocytoma.

Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28.

PMID:
30820715
14.

Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12.

Giordano FA, Link B, Glas M, Herrlinger U, Wenz F, Umansky V, Brown JM, Herskind C.

Cancers (Basel). 2019 Feb 26;11(3). pii: E272. doi: 10.3390/cancers11030272. Review.

15.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
16.

Blood-Based Biomarkers in High Grade Gliomas: a Systematic Review.

Pierscianek D, Ahmadipour Y, Oppong MD, Rauschenbach L, Kebir S, Glas M, Sure U, Jabbarli R.

Mol Neurobiol. 2019 Sep;56(9):6071-6079. doi: 10.1007/s12035-019-1509-2. Epub 2019 Feb 4. Review.

PMID:
30719642
17.

Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review.

Rauschenbach L, Kocakavuk E, Pierscianek D, Ahmadipour Y, Kebir S, Glas M, Scheffler B, Sure U, Jabbarli R.

Spinal Cord. 2019 Jun;57(6):439-448. doi: 10.1038/s41393-019-0248-6. Epub 2019 Feb 1. Review.

PMID:
30710121
18.

Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.

Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Mönninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M.

Clin Nucl Med. 2019 Mar;44(3):214-220. doi: 10.1097/RLU.0000000000002398.

PMID:
30516675
19.

Structural Analysis of the Interaction between the Bacterial Cell Division Proteins FtsQ and FtsB.

Kureisaite-Ciziene D, Varadajan A, McLaughlin SH, Glas M, Montón Silva A, Luirink R, Mueller C, den Blaauwen T, Grossmann TN, Luirink J, Löwe J.

MBio. 2018 Sep 11;9(5). pii: e01346-18. doi: 10.1128/mBio.01346-18.

20.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
21.

Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.

Kebir S, Rauschenbach L, Gielen GH, Schäfer N, Tzaridis T, Scheffler B, Giordano FA, Lazaridis L, Herrlinger U, Glas M.

J Clin Neurosci. 2018 Jul;53:255-258. doi: 10.1016/j.jocn.2018.04.056. Epub 2018 May 10.

PMID:
29754968
22.

Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.

Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, Lohmann P, Kebir S, Herrmann K, Fink GR, Langen KJ, Glas M, Galldiks N.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1626-1635. doi: 10.1007/s00259-018-3992-5. Epub 2018 Mar 21.

PMID:
29564490
23.

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial.

Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hänggi D, Schmiedek P, Emami B, Souhami L, Petrecca K, Wenz F.

Neurosurgery. 2019 Jan 1;84(1):41-49. doi: 10.1093/neuros/nyy018.

PMID:
29528443
24.

11C-MET PET/MRI for detection of recurrent glioma.

Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, Hense J, Quick HH, Glas M, Herrmann K, Umutlu L, Moenninghoff C, Radbruch A, Forsting M, Schlamann M.

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):593-601. doi: 10.1007/s00259-017-3916-9. Epub 2017 Dec 28.

PMID:
29282517
25.

Noninvasive Assessment of Intra-Abdominal Pressure Using Ultrasound-Guided Tonometry: A Proof-of-Concept Study.

Bloch A, Glas M, Kohler A, Baumann U, Jakob SM.

Shock. 2018 Dec;50(6):684-688. doi: 10.1097/SHK.0000000000001085.

26.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

27.

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients.

Hattingen E, Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Herrlinger U, Glas M, Kebir S.

Oncotarget. 2017 Jun 27;8(32):53542-53551. doi: 10.18632/oncotarget.18612. eCollection 2017 Aug 8.

28.

Neuroprotection with the P53-Inhibitor Pifithrin-μ after Cardiac Arrest in a Rodent Model.

Glas M, Frick T, Springe D, Putzu A, Zuercher P, Grandgirard D, Leib SL, Jakob SM, Takala J, Haenggi M.

Shock. 2018 Feb;49(2):229-234. doi: 10.1097/SHK.0000000000000917.

29.

Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial.

Herrlinger U, Schäfer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1815-1821. doi: 10.1007/s00432-017-2423-5. Epub 2017 Apr 22.

30.

18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor.

Kebir S, Kimmich O, Niehusmann P, Gaertner FC, Essler M, Landsberg J, Klockgether T, Simon M, Herrlinger U, Glas M.

Oncol Lett. 2016 Dec;12(6):4705-4707. doi: 10.3892/ol.2016.5234. Epub 2016 Oct 10.

31.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M.

Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

32.

Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.

Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E.

Cancer Med. 2017 Jan;6(1):89-99. doi: 10.1002/cam4.966. Epub 2016 Nov 28.

33.

A change of colloid from hydroxyethyl starch to gelatin does not reduce rate of renal failure or mortality in surgical critical care patients: Results of a retrospective cohort study.

Albrecht FW, Glas M, Rensing H, Kindgen-Milles D, Volk T, Mathes AM.

J Crit Care. 2016 Dec;36:160-165. doi: 10.1016/j.jcrc.2016.07.005. Epub 2016 Jul 9.

PMID:
27546766
34.

Impedance aggregometric analysis of platelet function of apheresis platelet concentrates as a function of storage time.

Glas M, Bauer JV, Eichler H, Volk T.

Scand J Clin Lab Invest. 2016 Dec;76(8):664-670. Epub 2016 Oct 5.

PMID:
27701904
35.

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U, Glas M.

Neuro Oncol. 2016 Oct;18(10):1462-4. doi: 10.1093/neuonc/now154. Epub 2016 Sep 2. No abstract available.

36.

Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.

Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM, Trageser D, Till A, Schäfer N, Glas M, Hillmer AM, Cichon S, Smith AA, Pietsch T, Liu Y, Reynolds BA, Yachnis A, Pincus DW, Simon M, Brüstle O, Steindler DA, Scheffler B.

Clin Cancer Res. 2017 Jan 15;23(2):562-574. doi: 10.1158/1078-0432.CCR-15-2089. Epub 2016 Aug 12.

37.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.

Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1825-9. doi: 10.1007/s00432-016-2187-3. Epub 2016 Jun 18.

PMID:
27318492
38.

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.

J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.

PMID:
27193554
39.

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.

Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21.

PMID:
27100354
40.

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schäfer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U.

Oncol Lett. 2016 Mar;11(3):2195-2198. Epub 2016 Feb 4.

41.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14.

PMID:
26976423
42.

Therapy of leptomeningeal metastasis in solid tumors.

Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M.

Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. Review.

PMID:
26827696
43.

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):321-322. doi: 10.1007/s00401-015-1523-z.

PMID:
26744347
44.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

45.

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y.

EMBO Mol Med. 2016 Jan 1;8(1):39-57. doi: 10.15252/emmm.201505505.

46.

Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):309-319. doi: 10.1007/s00401-015-1495-z. Epub 2015 Oct 22. Erratum in: Acta Neuropathol. 2016 Feb;131(2):321-2.

47.

The Soluble Periplasmic Domains of Escherichia coli Cell Division Proteins FtsQ/FtsB/FtsL Form a Trimeric Complex with Submicromolar Affinity.

Glas M, van den Berg van Saparoea HB, McLaughlin SH, Roseboom W, Liu F, Koningstein GM, Fish A, den Blaauwen T, Heck AJ, de Jong L, Bitter W, de Esch IJ, Luirink J.

J Biol Chem. 2015 Aug 28;290(35):21498-509. doi: 10.1074/jbc.M115.654756. Epub 2015 Jul 9.

48.

Melatonin or ramelteon therapy differentially affects hepatic gene expression profiles after haemorrhagic shock in rat--A microarray analysis.

Kleber A, Ruf CG, Wolf A, Fink T, Glas M, Wolf B, Volk T, Abend M, Mathes AM.

Exp Mol Pathol. 2015 Oct;99(2):189-97. doi: 10.1016/j.yexmp.2015.06.019. Epub 2015 Jun 25.

PMID:
26116814
49.

Evolutionary trends and functional anatomy of the human expanded autophagy network.

Till A, Saito R, Merkurjev D, Liu JJ, Syed GH, Kolnik M, Siddiqui A, Glas M, Scheffler B, Ideker T, Subramani S.

Autophagy. 2015;11(9):1652-67. doi: 10.1080/15548627.2015.1059558.

50.

Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.

Giessen-Jung C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Schulz C, Heinemann V, Di Gioia D, Stieber P.

Tumour Biol. 2015 Sep;36(10):7897-906. doi: 10.1007/s13277-015-3522-z. Epub 2015 May 8.

PMID:
25953265

Supplemental Content

Support Center